<DOC>
	<DOCNO>NCT00664859</DOCNO>
	<brief_summary>The current study design test long-term ( 12-month ) safety efficacy LCP-AtorFen , combination atorvastatin fenofibrate , patient dyslipidemia</brief_summary>
	<brief_title>12-Month , Open-Label , Extension Study LCP-AtorFen Dyslipidemia</brief_title>
	<detailed_description>POPULATION : Subjects mixed dyslipidemia ( non-HDL cholesterol &gt; 130 mg/dL TG ≥ 150 mg/dL ≤ 500 mg/dL ) complete double-blind study ( LCP-AtorFen-2001 ; NCT00504829 ) , meet enrollment criterion ( inclusion criterion none exclusion criterion ) , elect enter open-label extension study . STUDY DESIGN AND DURATION : This 52-week , open-label , single-treatment arm 8 visit ( Weeks 0 , 4 , 8 , 12 , 24 , 36 , 48 52 ) . A maximum approximately 200 subject enter open-label safety efficacy extension study LCP AtorFen-2001 double-blind study . All subject enrol study receive open-label LCP-AtorFen combination therapy . Visit 1 extension study corresponds last visit double-blind study ( Visit 6 Week 12 ) .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1 . Subject successfully complete doubleblind study ( LCPAtorFen2001 ; NCT00504829 ) . 2 . Subject confirm willingness participate study inform aspect study voluntarily sign date informed consent form accordance Good Clinical Practice ( GCP ) . 1 . Study drug compliance &lt; 70 % doubleblind study . 2 . Any ongoing serious adverse event , ongoing nonserious moderate severe adverse event doubleblind study rat possibly , probably definitely related study drug . 3 . Resting blood pressure &gt; /=160 mm Hg systolic and/or &gt; /=100 mm Hg diastolic . 4 . Symptoms unexplained muscle pain , tenderness weakness ( i.e. , sign indicative possible myopathy ) , diagnosis myopathy rhabdomyolysis . 5 . Any clinically significant change physical exam electrocardiogram Visit 2 Visit 6 doubleblind study . 6 . Any clinically significant change Visit 1 Visit 6 doubleblind study medical history include , limited : diagnosis insulindependent diabetes mellitus ( DM ) ; poorly control DM ; poorly control hypertension ; significant renal , pulmonary , hepatic , biliary , gastrointestinal disease ; cancer ( except nonmelanoma skin cancer ) ; epilepsy . 7 . Unwilling abstain medication , supplement , ingredient herbal therapy exclude doubleblind study continue exclude openlabel study . 8 . Women pregnant , plan pregnant study period , lactate , woman childbearing potential ( surgically sterilize menarche menopause ) use medically approve method contraception . 9 . Other exclusion condition might apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>LCP-AtorFen</keyword>
	<keyword>Non-HDL cholesterol</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>HDL cholesterol</keyword>
	<keyword>LDL cholesterol</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>